This report addresses the following questions:
– What impact have CER and HEOR had on drug reimbursement and uptake in the US so far?
– Who are the key generators and users of CER and HEOR data?
– How are new drug valuation frameworks such as ASCO, NCCN or ICER impacting drug reimbursement in the US?
– How is the use of outcome-based risk-sharing deals evolving in the US?
– What strategies will pharma companies need to employ to remain successful as payers look to derive greater value from new medicines?
For more information and how to order here. (Source: ResearchandMarkets, March 2016)